A Study to Evaluate the Tolerability, Safety, and Efficacy of an Anti-CD19 CAR-T Product in Patients With B-cell Lymphoproliferative Disorders
An Interventional Open-label, Single-group, Phase I/II Study to Evaluate the Tolerability, Safety, and Efficacy of an Anti-CD19 CAR-T Product in Adult Patients With Relapsed or Refractory Forms of B-cell Lymphoproliferative Disorders
Sponsor: National Research Center for Hematology, Russia
Listed as NCT06705530, this PHASE1/PHASE2 trial focuses on Acute Lymphoblastic Leukemia ALL and Non-Hodgkin Lymphoma, B-cell and remains completed. Sponsored by National Research Center for Hematology, Russia, it has been updated 4 times since 2024, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
4 versions recorded-
Feb 2026 — Present [monthly]
Completed PHASE1/PHASE2
Status: Recruiting → Completed
-
Sep 2025 — Feb 2026 [monthly]
Recruiting PHASE1/PHASE2
-
Jan 2025 — Sep 2025 [monthly]
Recruiting PHASE1/PHASE2
Status: Not Yet Recruiting → Recruiting
-
Dec 2024 — Jan 2025 [monthly]
Not Yet Recruiting PHASE1/PHASE2
First recorded
Nov 2024
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Research Center for Hematology, Russia
For direct contact, visit the study record on ClinicalTrials.gov .